Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01712061 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy
A Phase 2 study of Diabetic Nephropathy, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 226
- Enrollment target
- 20
- Study locations
NCT01712061: Completed Phase 2 study of Diabetic Nephropathy, sponsored by Pfizer.
NCT01712061 is a Phase 2 study of Diabetic Nephropathy that has completed, run by Pfizer. The registered enrollment target is 226 participants, below the 11,406-participant average among 9 other Diabetic Nephropathy trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01712061, a Phase 2 study of Diabetic Nephropathy, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 226 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study hypothesis under test is that administration of a CCR2/5 antagonist to subjects with type 2 diabetes and overt nephropathy will result in a reduction in urinary albumin, a surrogate for improved glomerular filtration.
Primary Outcome
The presence of albumin in the urine (macroalbuminuria) is a marker of kidney disease. Albumin and creatinine concentrations were obtained from spot urine samples.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PF-04634817
Study Locations (20)
California
- North America Research Institute - Azusa
- California Institute of Renal Research - Chula Vista
- California Kidney Specialists - Covina
- Diabetes/Lipid Management and Research Center - Huntington Beach
- Tower Nephrology Medical Group - Los Angeles
- Richard S. Cherlin, MD - Los Gatos
- Providence Clinical Research - North Hollywood
- Desert Oasis Healthcare Medical Group - Palm Springs
- Central Coast Nephrology - Salinas
- California Kidney Specialists - San Dimas
Florida
- Gulf Coast Endocrine and Diabetes Center - Clearwater
- Continental Research Corp. - Doral
- Premier Research Associate, Inc. - Hialeah
- Prestige Clinical Research Center - Miami
- Elite Clinical Research - Miami
- Nephrology Associates of South Miami - Miami
- Tellus Clinical Research, Inc. - Miami
- Ocean Blue Medical Research Center, Inc - Miami Springs
Arkansas
- Medical Investigations, Inc. - Little Rock
Colorado
- University of Colorado Denver/University of Colorado Hospital - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
What the finished NCT01712061 record still lists
NCT01712061 is an interventional study that assigns participants to a tested intervention. The registered 226 participants enrollment target is mid-sized for trials with a published cap, below the 11,406-participant average among 9 other Diabetic Nephropathy trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Diabetic Nephropathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01712061 names 20 study sites across 4 states, led by California, Florida, Arkansas.
Frequently Asked Questions
What is clinical trial NCT01712061 about?
NCT01712061 is a clinical study titled "A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy". The study hypothesis under test is that administration of a CCR2/5 antagonist to subjects with type 2 diabetes and overt nephropathy will result in a reduction in urinary albumin, a surrogate for improved glomerular filtration.
What is the current status of trial NCT01712061?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 226 participants. The study started on 2012-12. Estimated completion is 2014-09.
What conditions does trial NCT01712061 study?
This clinical trial studies the following conditions: Diabetic Nephropathy.
What interventions are being tested in trial NCT01712061?
The interventions under investigation include: Placebo (DRUG), PF-04634817 (DRUG).
Who is sponsoring clinical trial NCT01712061?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01712061 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01712061's enrollment target sits among peer trials
226 5th of 9 higher than 5 of 9 other Diabetic Nephropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Nephropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
COMPLETED · Phase 2
-
The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
COMPLETED · Phase 2
-
Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
COMPLETED · Phase 2
-
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
RECRUITING
-
Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
RECRUITING
-
Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04419272 · 226 participants · Phase 4
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
- NCT05449002 · 226 participants · NA
Digital Single Session Intervention for Youth Mental Health
- NCT05488054 · 226 participants · NA
Muscle O2 Saturation and Hemoglobin Levels During Rehabilitation From Arthroscopic Surgery
- NCT05924477 · 226 participants · NA
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia